Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian Cancer.

Heitz F, Kommoss S, Tourani R, Grandelis A, Uppendahl L, Aliferis C, Burges A, Wang C, Canzler U, Wang J, Belau A, Prader S, Hanker L, Ma S, Ataseven B, Hilpert F, Schneider S, Sehouli J, Kimmig R, Kurzeder C, Schmalfeldt B, Braicu EI, Harter P, Dowdy SC, Winterhoff BJ, Pfisterer J, du Bois A.

Clin Cancer Res. 2020 Jan 1;26(1):213-219. doi: 10.1158/1078-0432.CCR-19-1741. Epub 2019 Sep 16.

PMID:
31527166
2.

Clinical Outcome of Neoadjuvant Radiochemotherapy in Locally Advanced Cervical Cancer: Results of an Open Prospective, Multicenter Phase 2 Study of the North-Eastern German Society of Gynecological Oncology.

Koensgen D, Sehouli J, Belau A, Weiss M, Stope MB, Grokopf V, Eichbaum M, Ledwon P, Lichtenegger W, Zygmunt M, Köhler G, Mustea A.

Int J Gynecol Cancer. 2017 Mar;27(3):500-506. doi: 10.1097/IGC.0000000000000894.

PMID:
28187089
3.

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).

Sehouli J, Chekerov R, Reinthaller A, Richter R, Gonzalez-Martin A, Harter P, Woopen H, Petru E, Hanker LC, Keil E, Wimberger P, Klare P, Kurzeder C, Hilpert F, Belau AK, Zeimet A, Bover-Barcelo I, Canzler U, Mahner S, Meier W.

Ann Oncol. 2016 Dec;27(12):2236-2241. doi: 10.1093/annonc/mdw418. Epub 2016 Oct 26.

PMID:
27789470
4.

Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial.

Brucker J, Mayer C, Gebauer G, Mallmann P, Belau AK, Schneeweiss A, Sohn C, Eichbaum M.

Oncol Lett. 2016 Aug;12(2):1211-1215. Epub 2016 Jun 16.

5.

Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology).

Mustea A, Koensgen D, Belau A, Sehouli J, Lichtenegger W, Schneidewind L, Sommer H, Markmann S, Scharf JP, Ehmke M, Ledwon P, Braicu I, Zygmunt M, Koehler G.

Cancer Chemother Pharmacol. 2013 Nov;72(5):975-83. doi: 10.1007/s00280-013-2276-9. Epub 2013 Sep 1.

PMID:
23995698
6.

German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.

von Minckwitz G, Möbus V, Schneeweiss A, Huober J, Thomssen C, Untch M, Jackisch C, Diel IJ, Elling D, Conrad B, Kreienberg R, Müller V, Lück HJ, Bauerfeind I, Clemens M, Schmidt M, Noeding S, Forstbauer H, Barinoff J, Belau A, Nekljudova V, Harbeck N, Loibl S.

J Clin Oncol. 2013 Oct 1;31(28):3531-9. doi: 10.1200/JCO.2012.47.2167. Epub 2013 Aug 26.

PMID:
23980081
7.

Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.

Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S.

Ann Oncol. 2013 Sep;24(9):2316-24. doi: 10.1093/annonc/mdt162. Epub 2013 May 9.

PMID:
23661292
8.

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.

Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M.

Ann Oncol. 2013 Apr;24(4):937-43. doi: 10.1093/annonc/mds538. Epub 2012 Oct 26.

PMID:
23104722
9.

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.

Meier W, du Bois A, Rau J, Gropp-Meier M, Baumann K, Huober J, Wollschlaeger K, Kreienberg R, Canzler U, Schmalfeldt B, Wimberger P, Richter B, Schröder W, Belau A, Stähle A, Burges A, Sehouli J.

Gynecol Oncol. 2012 Aug;126(2):236-40. doi: 10.1016/j.ygyno.2012.04.050. Epub 2012 May 4.

PMID:
22564713
10.

A prospective multicenter study of treosulfan in elderly patients with recurrent ovarian cancer: results of a planned safety analysis.

Mahner S, Oskay-Özcelik G, Heidrich-Lorsbach E, Fuxius S, Sommer H, Klare P, Belau A, Ruhmland B, Heuser T, Kölbl H, Markmann S, Sehouli J.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1413-9. doi: 10.1007/s00432-012-1221-3. Epub 2012 Apr 15.

11.

A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.

Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel S.

Ann Oncol. 2012 Sep;23(9):2259-64. doi: 10.1093/annonc/mdr628. Epub 2012 Feb 21.

12.

Topotecan Weekly Versus Conventional 5-Day Schedule in Patients With Platinum-Resistant Ovarian Cancer: a randomized multicenter phase II trial of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.

Sehouli J, Stengel D, Harter P, Kurzeder C, Belau A, Bogenrieder T, Markmann S, Mahner S, Mueller L, Lorenz R, Nugent A, Wilke J, Kuznik A, Doering G, Wischnik A, Sommer H, Meerpohl HG, Schroeder W, Lichtenegger W, Oskay-Oezcelik G.

J Clin Oncol. 2011 Jan 10;29(2):242-8. doi: 10.1200/JCO.2009.27.8911. Epub 2010 Nov 29.

PMID:
21115872
13.

Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study.

Huober J, von Minckwitz G, Denkert C, Tesch H, Weiss E, Zahm DM, Belau A, Khandan F, Hauschild M, Thomssen C, Högel B, Darb-Esfahani S, Mehta K, Loibl S.

Breast Cancer Res Treat. 2010 Nov;124(1):133-40. doi: 10.1007/s10549-010-1103-9. Epub 2010 Aug 10.

PMID:
20697801
14.

Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study.

Koensgen D, Stengel D, Belau A, Klare P, Oskay-Oezcelik G, Steck T, Camara O, Mustea A, Sommer H, Coumbos A, Bogenrieder T, Lichtenegger W, Sehouli J; North-Eastern German Society of Gynecological Oncology Study Group-Ovarian Cancer.

Cancer Chemother Pharmacol. 2008 Aug;62(3):393-400. Epub 2007 Oct 9.

PMID:
17922272
15.

The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.

Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F.

Ann Oncol. 2006 Oct;17(10):1568-77.

16.
17.

Selective pretreatment diagnostic imaging for detecting remote metastases in patients with endometrial cancer.

Heyer H, Ohlinger R, Arndt D, Belau A, Nehmzow M, Hosten N, Köhler G.

Onkologie. 2006 Mar;29(3):85-9. Epub 2006 Mar 3.

PMID:
16514268
18.

A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).

du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck HJ, Schroeder W, Burges A, Olbricht S, Elser G; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

Gynecol Oncol. 2005 Feb;96(2):444-51.

PMID:
15661234
19.

Practicability of magnetoencephalography-guided neuronavigation.

Firsching R, Bondar I, Heinze HJ, Hinrichs H, Hagner T, Heinrich J, Belau A.

Neurosurg Rev. 2002 Mar;25(1-2):73-8.

PMID:
11954769

Supplemental Content

Support Center